DSIP
Delta Sleep-Inducing Peptide
DSIP is a naturally occurring nonapeptide first isolated from rabbit cerebral venous blood during slow-wave sleep. It is found in hypothalamic and limbic brain regions and in peripheral tissues. Research spans sleep promotion, stress hormone regulation (particularly cortisol reduction), antioxidant activity, and potential anti-aging applications through its effects on the hypothalamic-pituitary axis.
Mechanism of Action
DSIP modulates slow-wave (delta) sleep by interacting with multiple neurotransmitter systems — GABA-A, glutamate (NMDA), serotonin, and opioid receptors. This multi-system modulation produces sleep effects that are qualitatively different from single-receptor sleep aids — promoting deeper NREM sleep rather than simply inducing sedation.
DSIP reduces cortisol, ACTH, and LH release from the pituitary, which may explain its stress-normalising and HPA axis-dampening effects. The cortisol-reducing effect is particularly relevant for recovery protocols where chronically elevated cortisol impairs tissue healing.
Antioxidant properties include inhibition of lipid peroxidation and free radical scavenging. Some researchers propose that DSIP's combination of sleep improvement, cortisol reduction, and antioxidant activity produces a broadly protective effect on recovery and longevity.
Research Evidence
DSIP research dates to the 1970s. Much of the foundational work was conducted in European clinical settings. Modern research interest has revived due to its cortisol-modulating and sleep-enhancement properties.
DSIP Reduces Stress Hormones and Improves Sleep Quality in Insomnia
DSIP administration in patients with chronic insomnia produced significant reductions in sleep latency, increased slow-wave sleep duration, and normalised morning cortisol levels, with no sedation or hangover effect reported.
Typical Research Protocol
Often combined with Epithalon for longevity protocols (both support pineal/circadian regulation). Intranasal delivery is gaining research interest for CNS access.
Safety Profile
Reported Side Effects
- Mild daytime sedation (dose-dependent)
- Vivid dreams
- Headache (rare)
Contraindications
- Operating heavy machinery post-dose
- Pregnancy (no data)
- Depression (HPA suppression)
Common Research Stacks
Frequently Asked Questions
Is DSIP a sedative?
No — DSIP promotes the quality and depth of natural sleep rather than inducing sedation. Users typically report falling asleep more easily and achieving deeper slow-wave sleep, without next-day grogginess. It does not impair motor function or cognition at research doses.
How does DSIP reduce cortisol?
DSIP directly suppresses ACTH (adrenocorticotropic hormone) release from the pituitary, which in turn reduces cortisol production in the adrenal glands. This HPA axis dampening is why DSIP is studied for chronic stress recovery and overtraining syndrome. Unlike cortisol-blocking drugs, DSIP normalises rather than completely suppresses cortisol — supporting physiological adaptation rather than blunting it entirely.
Can DSIP be combined with Epithalon for sleep?
This is a common pairing in longevity protocols. DSIP promotes slow-wave sleep quality via multi-receptor CNS modulation, while Epithalon restores melatonin circadian rhythms via pineal stimulation. The two peptides support sleep through different and complementary mechanisms. Both are typically dosed in the evening 30–60 minutes before sleep.
Does DSIP work for insomnia?
Clinical research from the 1980s showed DSIP significantly reduced sleep latency, increased slow-wave sleep duration, and normalised morning cortisol in chronic insomnia patients. Unlike benzodiazepines, DSIP did not impair sleep architecture or produce dependence. However, this work was conducted 30+ years ago with small sample sizes — modern replications meeting current research standards are limited.
What is the intranasal route for DSIP?
Intranasal DSIP is an emerging administration route that may provide better CNS delivery than SC injection by utilising olfactory nerve transport, bypassing the blood-brain barrier. Research into intranasal formulation is limited but ongoing. SC administration remains the standard route with the most evidence. Intranasal may be preferred for those seeking non-injection administration.
Key Research References
- Monnier M et al. (1977). Humoral transmission of sleep. Science.
- Schoenenberger GA, Monnier M. (1977). Characterization of DSIP. Proc Natl Acad Sci.
Explore more Recovery research compounds
Browse Recovery →